Clinical Trial Update: Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BF2.649 for excessive daytime sleepiness in Parkinson's disease has completed, with results assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• BF2.649 (BF2.649)

Snippet

Sponsor: Bioprojet | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED